As senior director, Scientific Engagement for the Alzheimer’s Association®, Dr. Edelmayer leads efforts to accelerate the organization’s scientific agenda through the creation and delivery of ongoing research education. She engages with chapters across the country, ensuring that communities are informed of the global progress of dementia science and the organization’s crucial role in advancing research to improve the lives of those facing Alzheimer’s and all other dementia. Dr. Edelmayer provides leadership on several of the Association’s national and international initiatives in dementia science uniting researchers and clinicians on topics related to biomarker testing, drug discovery and therapeutic development. Dr. Edelmayer is a study investigator for the Association’s Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET), an initiative to gain insight on novel FDA-approved Alzheimer’s therapies. She also serves on steering committees and as an external advisory board member for various cutting-edge scientific consortia established by the National Institute on Aging to advance treatment development, including the Accelerating Medicines Partnership-Alzheimer’s Disease, MODEL-AD and TREAT-AD. ​ Dr. Edelmayer has more than 20 years of experience as a scientist and educator, spending more than six years as a pharmacologist in the Neuroscience and Immunology Divisions at Abbott and AbbVie. She has lectured, published and led collaborations in areas of neurodegenerative disease, neurophysiology, and pain neurobiology. She completed her Ph.D. and postdoctoral training in medical pharmacology at the University of Arizona College of Medicine. Dr. Edelmayer holds a bachelor’s degree in neuroscience from the University of Pittsburgh, where she also completed a NIMH research fellowship.

Dr. Grill has been the recipient of the National Alzheimer’s Coordinating Center Junior Investigator Award, the Alzheimer’s Association Turken Research Prize, the Community Spirit Award from OPICA Adult Day Services, and the P. Gene and Elaine Smith Term Chair in Alzheimer’s Disease Research. He has been funded by the National Institute on Aging, the National Institute of Neurological Disorders and Stroke, the Alzheimer’s Association, the BrightFocus Foundation, the Hartford Foundation, the American Federation for Aging Research, and the University of California. He is the co-leader of the Internal Ethics Committee and the Recruitment Unit for the NIA-funded Alzheimer's Clinical Trial Consortium. He is the Chair of the Internal Ethics Committee for the Alzheimer’s Disease Cooperative Study. He is a member of the Scientific Advisory Board for Maria Shriver’s Women’s Alzheimer’s Movement and for HFC (formerly Hilarity for Charity). In 2017, he co-chaired a workgroup as part of the NIH’s Inclusion Across the Lifespan workshop, a congressional mandate in the 21st Century Cures Act (P.L. 114-255). He is part of a working group sponsored by the National Institute on Aging and the Alzheimer’s Association charged with creating a national strategy for recruitment to Alzheimer’s disease clinical research. In 2021, he was an invited presenter and contributor to "A Workshop on Biomarkers and Other Pre-Clinical Diagnostics of Alzheimer's Disease," sponsored by the National Institute on Aging and convened by the National Academies of Science, Engineering, and Medicine.

Dr. Ritter is the Larkin Family Endowed Chair in Integrative Brain Health and Director of the Memory & Cognitive Disorders Program in Hoag’s Pickup Family Neurosciences Institute. Board certified by the American Board of Psychiatry and Neurology, he completed a residency in psychiatry at the University of Arizona and a two-year clinical/research fellowship in behavioral neurology at Cleveland Clinic, shaping his focus on how neurological diseases affect cognition and behavior. He has a focus in Alzheimer’s disease, Lewy body disease, chronic traumatic encephalopathy and frontotemporal dementia. A principal investigator on dozens of research studies and clinical trials, Dr. Ritter has received extramural funding from the National Institutes of Health and Alzheimer’s Drug Discovery Foundation, among others. Before joining Hoag, he was principal investigator for the Brain Health in Professional Athletes Study, the largest study of athletes exposed to repetitive head trauma. Voted a Top Doctor in the Las Vegas Valley by his peers, he received the Dr. Roy Martin 2019 Las Vegas HEALS Inspired Excellence in Healthcare Award and was named the 2018 Innovator Healthcare Hero by Nevada Business Magazine. His passion for medical education resulted in honors from Cleveland Clinic (Excellence in Teaching Award) and the University of Arizona (Dean’s List in Excellence in Teaching). Dr. Ritter has authored or co-authored peer-reviewed manuscripts, delivered clinical presentations and keynote addresses, and contributed to textbooks on Alzheimer’s and dementia. His commentary has appeared in the New York Times, ESPN and WebMD. He earned his medical degree from the University of Colorado.